Cholesterol Depletion Results in Site-specific Increases in Epidermal Growth Factor Receptor Phosphorylation due to Membrane Level Effects

STUDIES WITH CHOLESTEROL ENANTIOMERS*

Received for publication, April 25, 2003, and in revised form, October 1, 2003
Published, JBC Papers in Press, October 6, 2003, DOI 10.1074/jbc.M304332200

Emily J. Westover‡, Howard L. Brockman§, Rhoderick E. Brown§, and Linda J. Pike¶

From the Departments of ‡Molecular Biology and Pharmacology and ¶Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, Missouri 63110 and the §Hormel Institute, University of Minnesota, Austin, Minnesota 55912

* This work was supported by National Institutes of Health Grants GM64481 (to L. J. P.) and GM47969 (to D. F. C.) and Cardiovascular Research Training Grant 55935 (to E. J. W.), and a Lucille P. Markey predoctoral fellowship (to E. J. W.), and the Hormel Foundation and United States Public Health Service Grant GM45928 (to R. E. B.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: Dept. of Biochemistry and Molecular Biology, Washington University School of Medicine, 660 S. Euclid Ave., P. O. Box 8231, St. Louis, MO 63110. Tel.: 314-362-9592; Fax: 314-362-7183; E-mail: pike@biochem.wustl.edu.

Cholesterol is an essential component of mammalian membranes. It alters membrane fluidity, thickness, curvature, and permeability (1–6). In addition, cholesterol is an important constituent of lipid rafts, specialized membrane microdomains that are rich in cholesterol, sphingolipids, and saturated phospholipids (1, 6, 7). Through interactions with cholesterol, the acyl chains of phospholipids in lipid rafts pack tightly together and extend fully to create a liquid-ordered phase (7–9).

A subset of plasma membrane proteins selectively partition into the ordered environment of lipid rafts (1, 7, 10). Because of the large number of signaling proteins that are localized to lipid rafts, it has been postulated that these domains serve as regulatory platforms for some signal transduction pathways (11, 12). The epidermal growth factor (EGF)1 receptor is one of the proteins involved in signaling that is known to be enriched in lipid rafts (13–15).

A variety of studies have shown that EGF receptor function is affected by the levels of cholesterol, which is present at higher concentrations in lipid rafts than in the surrounding plasma membrane (16). Depletion of cholesterol from cells leads to an increase in both basal (17, 18) and EGF-stimulated (18, 19) receptor phosphorylation. The enhanced receptor tyrosine phosphorylation appears to be due to a rise in the intrinsic kinase activity of the receptor (19). Cholesterol depletion has also been shown to result in an increase in the number of cell-surface EGF-binding sites (19, 20) The increased EGF binding seems to result from an unmasking of receptors that are present on the surface of cells, but are unable to bind EGF in the presence of elevated levels of cholesterol (19, 20).

In addition to altering the intrinsic binding and kinase activity of the EGF receptor, cholesterol also modulates signaling events directly downstream of the EGF receptor. For example, depletion of cholesterol impairs the ability of EGF to stimulate phosphatidylinositol turnover (21). By contrast, cholesterol depletion leads to the enhancement of EGF-stimulated MAPK activity (22).

These observations suggest that cholesterol plays a significant role in modulating EGF receptor-mediated signaling. However, the molecular basis for these effects of cholesterol on EGF receptor function is not known. Cholesterol could affect EGF receptor function indirectly by influencing the physical
properties of the membrane, such as thickness, fluidity, or lateral domain formation (3, 23). Indeed, depletion of cholesterol leads to the loss of the EGF receptor from low density lipid raft domains (19, 21), suggesting that some of the effects of cholesterol on EGF receptor function could be mediated through the ability of the sterol to promote lateral membrane domain formation. Alternatively, cholesterol could bind specifically to the receptor, regulating its activity through allosteric mechanisms. In this study, we further characterize the effects of cholesterol depletion on EGF receptor function and address the question of whether the effects of cholesterol are due to membrane level effects of the compound or result from specific molecular recognition of the sterol.

We report here that the enhanced basal and hormone-stimulated phosphorylation of the EGF receptor that occurs upon cellular cholesterol depletion is due to a selective increase in the phosphorylation of a subset of the phosphorylatable tyrosine residues in the C-terminal tail of the receptor. Using natural cholesterol (nat-cholesterol) and its enantiomer (ent-cholesterol), we provide evidence that the effects of cholesterol on EGF receptor function are most likely due to non-enantioselective effects of the sterol on membrane properties such as fluidity and the ability to form rafts.

EXPERIMENTAL PROCEDURES

Materials

EGF was prepared by the method of Savage and Cohen (24). The anti-phosphotyrosine monoclonal antibody PY20 was from Transduction Laboratories (Lexington, KY). Polyclonal antibodies against Tyr(P)^1173 of the EGF receptor were purchased from Cell Signaling Technology (Beverly, MA). A monoclonal antibody against Tyr(P)^1772 of the EGF receptor was from Upstate Biotechnology, Inc. (Lake Placid, NY). The anti-flotillin monoclonal antibody was from BD Transduction Laboratories (San Diego, CA). Polyvinylidene fluoride membranes were from Osmotics, Inc. (Westborough, MA). The enhanced chemiluminescence kit was from Amersham Biosciences. The cholesterol CII and free cholesterol E assay kits were from Wako Bioproducts (Richmond, VA). Methyl-β-cyclodextrin was from Aldrich. Egg sphingomyelin and (25S,3R,4E)-2-stearoylaminooctadec-4-ene-3-hydroxy-1-phosphocholine (N-stearoylsphingomyelin) were from Avanti Polar Lipids (Alabaster, AL). All other chemicals were from Sigma.

Methods

Cell Culture—A431 cells were maintained at 37°C and 5% CO2 in Dulbecco’s modified Eagle’s medium (DMEM) containing 7% newborn calf serum and 3% fetal calf serum. Cells were incubated overnight in DMEM containing 0.1% newborn calf serum prior to use. Chinese hamster ovary cells were maintained at 37°C, 1.0, in CHCl3). Fig. 1 shows the structures of nat- and ent-cholesterol.

Preparation of Cholesterol-Methyl-β-cyclodextrin Complexes—Cholesterol-methyl-β-cyclodextrin complexes were synthesized as described previously (25). Silyl-protected ent-desmosterol was subjected to catalytic hydrogenation (300 p.s.i. H2, 15 min, platinum/carbon) and then treated with the protecting group to give ent-cholesterol in m.p. 147.5–148°C, [α]D^20 = +40.0 C (C, 1.0, in CHCl3)). Fig. 1 shows the structures of nat- and ent-cholesterol.

Preparation of Cholesterol-Methyl-β-cyclodextrin Complexes—Cholesterol-methyl-β-cyclodextrin complexes were synthesized as described by Klein et al. (26). Briefly, 30 mg of nat- or ent-cholesterol was dissolved in 400 μl of isooctanol alcohol/chloroform (2:1, v/v). Methyl-β-cyclodextrin (1 g) was dissolved in 11 ml of phosphate-buffered saline (PBS) and heated to 80°C with stirring. The solubilized sterol was added in small aliquots to the heated solution over 30 min.

Cholesterol Depletion and Repletion—For cholesterol depletion, cells were incubated for 30 min at 37°C in DMEM containing 50 mM HEPES (pH 7.2) and 0.1% bovine serum albumin (DMEM/BSA) and the indicated concentration of methyl-β-cyclodextrin. Control cells were incubated in the same medium lacking cyclodextrin. To replete cells with cholesterol following cyclodextrin treatment, cells were incubated at 37°C for 30 min in DMEM/BSA containing the indicated concentration of steroylcyclodextrin complex. For both cholesterol depletion and repletion, the tissue culture plates were swirled every 10 min to ensure continuous mixing of the components in the medium.

Cholesterol Assay—Cells were washed twice with 1 ml of cold PBS, and lipids were extracted with 2 ml of hexane/isopropyl alcohol (3:2, v/v) for 1 h at room temperature. The organic extract was removed from the cell monolayer, and the solvent was removed in a SpeedVac. The lipid residue was solubilized in 1 ml of the cholesterol CII assay kit buffer solution. As reported previously (27), color generation from nat-cholesterol standards reached a plateau after 5 min at 37°C and remained stable through 60 min at this temperature, whereas ent-cholesterol standards required 60 min at 37°C for complete color development. Samples were incubated for 1 h at 37°C prior to measuring absorbance at 505 nm.

After lipid extraction, the residual cell monolayers were solubilized with 10 mM sodium borate and 1% SDS. Aliquots of the solubilized material were then used for determination of total protein content using the bicinchoninic acid protein assay.

Cholesterol Oxidase Assay—Assay of cholesterol oxidase was carried out utilizing the free cholesterol E assay kit. The free cholesterol E assay reagent contains cholesterol oxidase plus several additional components (peroxidase, 4-aminophenylpyrene, and DEHSA (3-((5,5-dimethyl-2-hydroxyphenyl)ethylamino)-2-hydroxy-1-propanoic acid monosodium salt) that permit the colorimetric detection of the hydrogen peroxide produced upon oxidation of cholesterol. For assay, 5 μg of either nat- or ent-cholesterol in complex with cyclodextrin was placed in a glass tube. One ml of the free cholesterol E assay kit buffer solution was then added. Samples were incubated at 37°C for the indicated times. The absorbance of the samples at 600 nm was measured immediately. Equal concentrations of free cholesterol and cyclodextrin-complexed cholesterol gave equivalent absorbance measurements in this assay.

Cell-surface EGF Binding—A431 cells were grown to confluence in 24-well dishes and incubated overnight in DMEM containing 0.1% fetal calf serum. After treatment to alter cholesterol content, cultures were washed with ice-cold PBS and incubated for 2 h at 4°C in 1 ml of DMEM/BSA, 50 μM 125I-EGF, and increasing concentrations of unlabelled EGF. At the end of the incubation, cells were washed three times with ice-cold PBS. Cell monolayers were dissolved in 1 ml of 1 M NaOH and counted for 125I. Data were analyzed using the LIGAND computer program (28).

Stimulation of Cells with EGF and Preparation of Cell Lysates—Cells in 35-mm dishes were treated to alter cholesterol content as outlined above. At the end of the incubation, EGF was added to the medium for 5 min. Cells were then washed with cold PBS and lysed by scraping the monolayers into 300 μl of radioimmune precipitation assay buffer (10 mM Tris (pH 7.2), 150 mM NaCl, 0.1% SDS, 1% Triton X-100, 1% deoxycholate, and 5 mM EDTA) containing 1 μg/ml leupeptin, 100 μM sodium o-phenan-drene, 10 mM p-nitrophenyl phosphate, and 1 mM phenylmethylsulfonyl fluoride. Lysates were incubated on ice for 10 min with periodic vortexing and then clarified by centrifugation at 12000 × g for 10 min. Aliquots were then taken for determination of total protein concentration. Receptor tyrosine phosphorylation was determined by Western blotting.

EGF Receptor Phosphorylation—To assess the rate of EGF receptor phosphorylation, cholesterol-depleted or cholesterol-repleted cells were stimulated with 1.25 nM EGF for 5 min at 37°C. The medium was removed, and cells were washed with cold PBS. Residual cell surface-bound EGF was removed by incubating the cells twice for 2 min in 50 mM glycine and 100 mM NaCl (pH 4.0) on ice. After an additional wash
with cold PBS, warmed DMEM/BSA was added, and the cells were incubated at 37 °C for the indicated times. Cells were washed with PBS and lysed with radioimmune precipitation assay buffer as usual. Receptor tyrosine phosphorylation was determined by Western blotting.

**Membrane Preparation and in Vitro Phosphorylation Assays—**Cells were treated to alter cholesterol levels and then lysed by homogenization in 25 mM Tris (pH 7.2). Membranes were pelleted by centrifugation for 10 min at 12000 × g and resuspended in 70 mM β-glycerophosphate, 250 mM NaCl, and 25% glycerol (pH 7.2). Assays were carried out in a final volume of 50 μl containing 20 mM β-glycerophosphate, 100 μM ATP, 12 mM MgCl₂, 2 mM MnCl₂, 20 mM p-nitrophenyl phosphate, 100 μM sodium o-vanadate, and 1 μg of membrane protein. When included, EGF was added at a final concentration of 25 nM. Membranes were incubated with growth factor for 5 min at room temperature. Assays were begun by the addition of ATP and metal ions. After incubation at 30 °C for 15 s, reactions were stopped by the addition of 50 μl of SDS sample buffer. Samples were boiled, run on a 10% SDS-polyacrylamide gel, and analyzed by Western blotting.

**Preparation of Lipid Rafts—** All manipulations were performed at 4 °C. After appropriate treatments, one 150-mm plate of A431 cells was washed five times with PBS and scraped into 0.4 ml of 0.25 M sucrose, 1 mM EDTA, and 20 mM Tris (pH 7.8). Cells were lysed by passage through a 23-gauge needle 10 times. The lysates were sonicated five times for 15 s using a Branson 250 sonicator set at maximal power output for a micropipet. After centrifugation at 1000 × g for 10 min, the post-nuclear supernatant was mixed with an equal volume of 85% sucrose in MES-buffered saline (25 mM MES (pH 6.5), 150 mM NaCl, and 2 mM EDTA) and placed in the bottom of a centrifuge tube. A 15–35% discontinuous sucrose gradient was formed above the lysate by adding sucrose-containing buffers as follows: 2 ml of 35% sucrose, 2 ml of 25% sucrose, 2 ml of 22% sucrose, and 4 ml of 15% sucrose, all in MES-buffered saline. The gradient was centrifuged for 18 h at 210,000 × g in an SW 41 rotor (Beckman Instruments). After discarding the uppermost 4 ml, the gradient was fractionated into eight 1-ml fractions. Then, 100–μl aliquots of each fraction were subjected to SDS-PAGE and analyzed by Western blotting.

**Cholesterol Effects on EGF Receptor Phosphorylation**

**Site-specific Effect of Cholesterol on EGF Receptor Phosphorylation—** A431 cells were treated with or without the indicated concentrations of methyl-β-cycloextrin for 30 min to remove cholesterol. Cells were lysed and analyzed for receptor phosphorylation by Western blotting with anti-phosphotyrosine antibody PT20. Results were quantitated by densitometry.

**RESULTS**

**Site-specific Effect of Cholesterol on EGF Receptor Phosphorylation—** A431 cells were treated with increasing concentrations of methyl-β-cycloextrin for 30 min to remove cholesterol. Lysates were prepared and analyzed for receptor tyrosine phosphorylation by SDS-PAGE and Western blotting with an anti-phosphotyrosine antibody. As shown in Fig. 2A, cholesterol depletion increased basal tyrosine phosphorylation of the EGF receptor up to 11-fold. The dose of methyl-β-cycloextrin yielding maximal stimulation was 7.5 mM when confluent cultures were used. However, when significantly subconfluent cells were used, the optimal concentration of methyl-β-cycloextrin was 2–3-fold less than this. This indicates that it is the ratio of cells to reagent that is important rather than the absolute concentration of reagent added.

In addition to enhancing basal EGF receptor phosphorylation, cholesterol depletion also increased EGF-stimulated receptor phosphorylation at all doses of EGF tested (Fig. 2B). At the maximal dose of EGF, receptor phosphorylation was enhanced from 1.2- to 2.0-fold in different experiments. The EC₅₀ for EGF was 2 nM and was essentially unchanged following cholesterol depletion. Thus, the increase in EGF-stimulated tyrosine phosphorylation of the receptor following cholesterol depletion appears to be due to a change in the maximal level of phosphorylation rather than to a change in the EC₅₀ for EGF.

The increase in EGF receptor phosphorylation was associated with only a modest increase in the number of cell-surface EGF-binding sites (Fig. 3). Scatchard analysis indicated the
presence of a single class of EGF-binding sites on control cells that exhibited a $K_d$ of $\sim 10$ nM. Cyclodextrin treatment resulted in an $\sim 10\%$ increase in the number of EGF-binding sites present on A431 cells with no change in the binding affinity of EGF.

The EGF receptor contains several tyrosine residues that become phosphorylated in response to EGF. To determine whether all sites were similarly affected by cholesterol depletion, EGF receptor phosphorylation was analyzed using a panel of antibodies that recognize specific phosphorylated tyrosine residues on the receptor. The data in Fig. 4 show that cholesterol depletion differentially affected the phosphorylation of individual tyrosine residues. Cholesterol depletion routinely enhanced the EGF-stimulated phosphorylation of tyrosines 845, 992, and 1173. By contrast, the level of hormone-stimulated phosphorylation of tyrosines 1045 and 1068 was relatively unaffected by removal of cholesterol. In all cases, cholesterol depletion did not significantly alter the $EC_{50}$ for receptor phosphorylation. These data indicate that cholesterol depletion induces site-specific changes in phosphorylation of the EGF receptor.

Comparison of the Enantiomers of Cholesterol—The effect of cholesterol depletion on EGF receptor phosphorylation could be due either to an effect of cholesterol on the physical properties of the membrane or to direct interaction of the sterol with the EGF receptor or another protein that regulates receptor phosphorylation. Theoretically, the use of cholesterol enantiomers should allow discrimination between these two possibilities. Because the physical properties of nat-cholesterol and its enantiomer, ent-cholesterol, are identical, their effects on general membrane properties should not be significantly different. However, because the two enantiomers have mirror image shapes, they should interact differently with molecules, such as proteins, that contain a stereospecific binding site for the sterol. To determine whether cholesterol affects EGF receptor function due to general membrane level effects or to direct binding to a protein, the enantiomer of cholesterol was synthesized (25) and used as a tool to probe the effects of cholesterol on EGF receptor function.

The ability of nat- and ent-cholesterol to interact with lipids and proteins was first compared in model systems to characterize the behavior of these two enantiomers in sterol-protein and sterol-lipid interactions. To assess the characteristics of nat- and ent-cholesterol when interacting specifically with a protein, the ability of cholesterol oxidase to use these enantiomers as substrates was compared. As shown in Fig. 5, nat-cholesterol was rapidly oxidized by cholesterol oxidase in a standard cholesterol assay system. The oxidation of nat-cholesterol was essentially complete within 30 s under these conditions and showed a $t_{1/2}$ of $<10$ s. By contrast, ent-cholesterol was much more slowly oxidized by cholesterol oxidase under the same conditions. Approximately 30 min were required for complete oxidation of this enantiomer. The reaction had a $t_{1/2}$ of 10 min. Thus, nat- and ent-cholesterol show clearly distinct behaviors when interacting with a protein that has a specific sterol-binding site.

The capacity of nat- and ent-cholesterol to interact with other lipids was first examined by comparing the ability of these two enantiomers to condense sphingomyelins in a monolayer system. Because lipid rafts are thought to be held together via cholesterol-sphingolipid interactions, this represents a good measure of the raft-forming capabilities of these enantiomers.
Fig. 6. Condensation of lipids by nat- and ent-cholesterol in monolayers. Surface pressure versus average molecular area behavior was measured as described under “Experimental Procedures” for pure nat-or ent-cholesterol or mixtures of these enantiomers with sphingomyelin. □ and ○, isotherms for pure nat- and ent-cholesterol, respectively; ▽ and ⌞, isotherms for 30 mol % nat- and ent-cholesterol, respectively, mixed with 70 mol % egg sphingomyelin; □ and △ isotherms for 30 mol % nat- and ent-cholesterol, respectively, mixed with 70 mol % N-stearoylsphingomyelin (the naturally occurring form of this lipid); ▽ and ⌞, isotherms for 1:1 mixtures of nat- and ent-cholesterol, respectively, with palmitoyloleylophosphatidylcholine. Each trace represents the average of three or more experimental isotherms. The standard errors are shown. mNm, milli-Newton meter.

Fig. 6 shows the surface pressure-average molecular area isotherms for mixtures of 70 mol % egg sphingomyelin and 30 mol % nat- or ent-cholesterol (open and closed circles, respectively). The isotherms were indistinguishable for the two enantiomers. This similarity in behavior was not the result of heterogeneity in the acyl chains present in the egg sphingomyelin mixture. When enantiomerically pure N-stearoylsphingomyelin was used in place of the egg sphingomyelin, the isotherms observed for mixtures with nat- and ent-cholesterol were again indistinguishable (Fig. 6, open and closed squares). The isotherms of pure nat- and ent-cholesterol were also identical (Fig. 6, open and closed inverted triangles). In addition, the force-area behavior of 1:1 mixtures of either nat- or ent-cholesterol with palmitoyloleylophosphatidylcholine were the same (Fig. 6, open and closed diamonds). The condensing effect of cholesterol is a well established indicator of its lateral interaction and non-ideal mixing with membrane phospholipids and sphingolipids (29, 34, 35). Therefore, these data indicate that the absolute configuration of the sterol does not affect its interaction with either phosphatidylcholine or sphingomyelin.

Effects of nat- and ent-Cholesterol on the EGF Receptor Are Similar.—The cholesterol enantiomers were next used in the A431 cell system to determine whether the effect of cholesterol on EGF receptor phosphorylation is the result of general sterol-lipid or stereospecific sterol-protein interactions. A431 cells were depleted of cholesterol and subsequently repleted with either nat- or ent-cholesterol using complexes of each sterol with methyl-β-cyclodextrin. The data in Table I confirm that treatment of cells with the same concentration of either sterol-cyclodextrin complex added a similar amount of each sterol to cholesterol-depleted cells.

nat- and ent-cholesterol exhibited similar abilities to reverse the effects of cholesterol depletion on both basal (Fig. 7A) and EGF-stimulated (Fig. 7B) receptor phosphorylation. Basal EGF receptor phosphorylation was enhanced 6-fold by the depletion of cholesterol. nat-Cholesterol reversed this effect, exhibiting an EC50 of between 0.07 and 0.2 mM. ent-Cholesterol reversed the effects of cholesterol depletion on basal EGF phosphorylation to the same extent as nat-cholesterol and exhibited an EC50 in the same range as that for the natural enantiomer. nat- and ent-cholesterol also exhibited similar potencies and efficacies for reversing the enhancement of EGF-stimulated receptor phosphorylation induced by cholesterol depletion (Fig. 7B).

To determine whether the similar effects of nat- and ent-

| Condition | Cholesterol |
|-----------|-------------|
| Control   | 32 ± 3      |
| +Cyclodextrin | 20 ± 2    |
| +nat-Cholesterol | 0.02 mM | 23 ± 3 |
|           | 0.07 mM | 26 ± 3 |
|           | 0.20 mM | 38 ± 4 |
| +ent-Cholesterol | 0.02 mM | 25 ± 3 |
|           | 0.07 mM | 28 ± 3 |
|           | 0.20 mM | 39 ± 4 |

Fig. 7. Effect of cholesterol repletion on phosphorylation of the EGF receptor. A, A431 cells were treated without (control (CON)) or with 7.5 mM methyl-β-cyclodextrin (CDX) to remove cholesterol. Some cultures were subsequently repleted with cholesterol by incubation with either nat-cholesterol (NAT) or ent-cholesterol (ENT) in complex with methyl-β-cyclodextrin. Concentrations given refer to the amount of cholesterol added. Cells were lysed and analyzed for receptor phosphorylation by Western blotting with anti-phosphotyrosine antibody PY20. Results were quantified by densitometry. B, cells were treated as described for A, but prior to lysis, cells were stimulated with 5 nM EGF for 5 min.
tent and over the same dose range by repletion of the cells with nat- and ent-cholesterol. Thus, the effects of these enantiomers on EGF receptor autophosphorylation appear to be independent of cell type and the level of receptor expression.

Cholesterol Affects EGF Receptor Kinase (but Not Phosphatase) Activity—The observed increase in receptor phosphorylation upon cholesterol depletion could be due either to a decrease in the activity of a protein-tyrosine phosphatase or to an increase in the intrinsic kinase activity of the receptor. To determine whether cholesterol affects the dephosphorylation of the EGF receptor, A431 cells were depleted of cellular cholesterol and then repleted with either nat- or ent-cholesterol. Following a 5-min stimulation with EGF, cells were washed with a low pH glycine buffer to remove cell-surface EGF. Subsequently, the cells were incubated for increasing lengths of time in EGF-free medium at 37 °C. Cells were lysed and analyzed for EGF receptor phosphorylation.

The data in Fig. 9 show that, as expected, the absolute amount of receptor phosphorylation was higher at all times in cholesterol-depleted cells than in untreated control cells. However, the rate of receptor dephosphorylation was similar in these two treatment groups. Control and cholesterol-depleted cells both exhibited $t_{1/2}$ values for receptor dephosphorylation in the range of 20–25 min. Cells repleted with either nat- or ent-cholesterol showed similar rates of dephosphorylation, with $t_{1/2}$ values of ~20 min. These data suggest that receptor dephosphorylation is not significantly affected by either the absolute level of cholesterol in the membrane or its absolute configuration.

To determine whether cholesterol levels or the absolute configuration of the sterol affects the intrinsic kinase activity of the EGF receptor, A431 cells were depleted of cholesterol and subsequently repleted with equal amounts of either nat- or ent-cholesterol. A total membrane fraction was then prepared and assayed for EGF receptor autophosphorylation in an in vitro system containing phosphatase inhibitors. The results are shown in Fig. 10. Both basal receptor phosphorylation and EGF-stimulated receptor phosphorylation were increased in membranes prepared from cells depleted of cholesterol. Repletion with nat- or ent-cholesterol reversed the effect of cholesterol depletion on basal and EGF-stimulated EGF receptor phosphorylation to a similar extent. These data suggest that intrinsic EGF receptor kinase activity is affected by cholesterol levels, but not by the absolute configuration of the sterol.

nat- and ent-Cholesterol Support Lipid Raft Formation—Cholesterol depletion disrupts lipid rafts and leads to the loss of the EGF receptor from these low density membrane domains (19, 21). Repletion of cholesterol leads to the reconstitution of lipid rafts and the relocalization of the EGF receptor to these domains (19, 21). An experiment was therefore performed to determine whether nat- and ent-cholesterol exhibit similar abilities to reconstitute lipid rafts in cholesterol-depleted cells.

A post-nuclear supernatant was prepared from A431 cells that had been depleted of cholesterol and then repleted with ent-cholesterol. Assay of this material for cholesterol indicated that 40% of the cholesterol present in these starting membranes was ent-cholesterol. Non-detergent lipid rafts were then prepared from the post-nuclear supernatant. In the lipid raft
cultures were subsequently repleted with cholesterol by incubation for 30 min with 0.2 mM nat-cholesterol (NAT) or ent-cholesterol (ENT) in complex with methyl-β-cyclodextrin. Lipid rafts were prepared as described under “Experimental Procedures.” Equal aliquots of fractions from the sucrose density gradient were analyzed by SDS-PAGE and Western blotting for the EGF receptor or flotillin.

fraction derived from these starting membranes, 41% of the cholesterol was determined to be ent-cholesterol. In a separate experiment, a 1% Triton X-100 extract was made from cells that had been depleted of cholesterol and repleted with ent-cholesterol. In this experiment, 54% of the cholesterol in the Triton X-100 extract was ent-cholesterol. After flotation in a sucrose gradient, the resulting Triton X-100-resistant lipid rafts were assayed and found to contain 60% ent-cholesterol. These data indicate that ent-cholesterol partitions into both non-detergent and Triton X-100-resistant lipid rafts in direct proportion to its concentration in the starting membranes.

A431 cells were depleted of cholesterol using methyl-β-cyclodextrin and repleted with equal amounts of either nat- or ent-cholesterol. Non-detergent lipid rafts were then prepared by sucrose density gradient centrifugation, and the distribution across the gradient of the EGF receptor and flotillin, a lipid raft marker protein, was assessed. The results are shown in Fig. 11. As expected, both the EGF receptor and flotillin selectively partitioned into the low density portion of the gradient in untreated cells. Depletion of cholesterol using methyl-β-cyclodextrin resulted in the loss of both proteins from the low density region of the gradient and their recovery in higher density fractions. Repletion of cells with nat-cholesterol reconstituted the lipid rafts, restoring the partitioning of flotillin and the EGF receptor into the low density fractions of the gradient. Similarly, reppletion with ent-cholesterol led to the movement of both flotillin and the EGF receptor back into the low density region of the gradient. These data suggest that nat- and ent-cholesterol have similar capacities to reconstitute lipid rafts and to promote partitioning of the EGF receptor into these low density membrane domains.

DISCUSSION

Cholesterol Depletion—The ability of cholesterol depletion to enhance EGF receptor phosphorylation has been observed by several groups (17–19). In this study, we provide additional details regarding the characteristics of cholesterol-modulated EGF receptor phosphorylation and provide insight into the molecular basis of this phenomenon.

In A431 cells, cholesterol depletion by methyl-β-cyclodextrin was found to enhance both basal and EGF-stimulated receptor tyrosine phosphorylation. The increase in ligand-dependent phosphorylation of the EGF receptor observed in these studies was found to be due to an increase in the maximal level of receptor phosphorylation rather than a change in the EC50 for EGF. Only an ~10% increase in EGF receptor number was observed in A431 cells following cholesterol depletion. Because this is substantially smaller than the percent increase in EGF-stimulated autophosphorylation observed in our experiments, the enhancement of EGF receptor phosphorylation cannot be attributed solely to a rise in surface-exposed EGF receptors.

We (19) and others (18, 20) have observed that cholesterol depletion leads to an increase in the number of cell-surface EGF receptors in a variety of other cell types. Evidence suggests that this increase is due to the unmasking of cryptic receptors present on the cell surface (18, 19). Recent structural studies of the extracellular domain of the EGF receptor offer insight into a possible molecular mechanism for this effect. The unliganded EGF receptor exists in a bent autoinhibited configuration that is stabilized by interactions between loops in the second and fourth extracellular subdomains (36). It apparently binds EGF only weakly (36). This bent inactive conformation is likely in equilibrium with an open configuration that binds EGF with high affinity and is capable of forming functionally active receptor dimers (37, 38). EGF shifts this equilibrium from the inactive to the active configuration of the receptor by binding to and stabilizing the open form (36, 38). The observation that cholesterol depletion results in an increase in EGF binding with no change in the amount of receptor protein detectable at the cell surface (19) suggests that high cholesterol levels may stabilize the intramolecular interactions, increasing the fraction of the EGF receptor that is in the inactive conformation. Cholesterol depletion would reduce this intramolecular stabilization, allowing the receptor to more readily adopt the open conformation necessary for tight EGF binding.

The increase in EGF receptor phosphorylation in response to cholesterol removal could be due to an increase in the intrinsic kinase activity of the receptor or to a decrease in the rate of receptor dephosphorylation. Cell culture experiments demonstrated that the t1/2 for receptor dephosphorylation was similar in control and cyclodextrin-treated cells. By contrast, following cholesterol depletion, EGF receptor autophosphorylation was enhanced in in vitro experiments, in which kinase activity was assayed in the presence of phosphatase inhibitors. Together, these data suggest that it is primarily an increase in intrinsic receptor kinase activity that gives rise to enhanced receptor phosphorylation in intact cells depleted of cholesterol. This is consistent with recent observations made in NIH 3T3 cells (19).

A novel finding with respect to the increase in EGF receptor phosphorylation following cholesterol depletion is that there was a selective increase in the phosphorylation of some sites, with little or no effect on the phosphorylation of other sites. Tyrosines 992, 1045, 1068, and 1173 are all known sites of EGF receptor autophosphorylation (39, 40). However, the phosphorylation following cholesterol depletion could be due to an increase in the intrinsic kinase activity of the receptor or to a decrease in the rate of receptor dephosphorylation. Cell culture experiments demonstrated that the t1/2 for receptor dephosphorylation was similar in control and cyclodextrin-treated cells. By contrast, following cholesterol depletion, EGF receptor autophosphorylation was enhanced in in vitro experiments, in which kinase activity was assayed in the presence of phosphatase inhibitors. Together, these data suggest that it is primarily an increase in intrinsic receptor kinase activity that gives rise to enhanced receptor phosphorylation in intact cells depleted of cholesterol. This is consistent with recent observations made in NIH 3T3 cells (19).

Tyrosine 845 is a site on the EGF receptor known to be phosphorylated by pp60src (41, 42). The observation that the phosphorylation of this site was selectively enhanced by cho-
Cholesterol depletion implies that either this site becomes more accessible to pp60src in cholesterol-depleted cells or that cholesterol depletion enhances the activation of pp60src in response to EGF. Phosphorylation of Tyr1045, which is in the activation loop of the kinase domain, is associated with an increase in the kinase activity of the EGF receptor (41). It is therefore possible that the increase in the intrinsic kinase activity of the EGF receptor that occurs following cholesterol depletion is a result of the enhanced phosphorylation of the receptor at Tyr1045. Additional studies will be required to clarify the molecular basis of this effect.

Specific phosphorylated tyrosine residues on the EGF receptor serve as binding sites for adaptor proteins and enzymes (43–46). The finding that a decrease in membrane cholesterol levels leads to selective increases in the phosphorylation of specific tyrosine residues suggests that cholesterol depletion could preferentially enhance signaling via specific pathways. For example, Shc binds selectively to Tyr1173, a residue whose phosphorylation is selectively enhanced in cholesterol-depleted cells (44). Thus, the MAPK pathway would be expected to be activated to a greater extent in cyclodextrin-treated cells than cells (44). This suggests that the increased kinase activity of the receptor is not counterbalanced by a Cbl-mediated increase in receptor internalization and down-regulation. The up-regulation of kinase activity without a concomitant increase in the negative regulatory mechanisms could serve to further enhance the relative signaling capacity of the EGF receptor in cholesterol-depleted cells.

Enantiomers of Cholesterol—The ability of cholesterol to modulate EGF receptor function could arise from several sources, including alterations in specific sterol-protein interactions, or from more general effects of the sterol on membrane structure. To distinguish between these two possibilities, the enantiomer, or mirror image, of cholesterol was synthesized and used in experiments in which nat-cholesterol was replaced by its enantiomer, ent-cholesterol. Preliminary experiments using cholesterol oxidase demonstrated that an enzyme possessing a specific binding site for cholesterol is capable of distinguishing between the enantiomers of cholesterol. Such enantioselective interactions appear to be absolutely required for viability of organisms, as our previous work has shown that substitution of ent-cholesterol for nat-cholesterol in the growth medium of Caenorhabditis elegans results in 100% lethality in second generation animals (47). Thus, proteins and intact organisms can distinguish nat-cholesterol from ent-cholesterol.

By contrast, in the monolayer experiments in which sterol-lipid interactions were examined, the enantiomers of cholesterol were indistinguishable in terms of their ability to condense sphingomyelin and phosphatidylcholine. This result is consistent with recent studies that have found that artificial bilayers containing sphingomyelin and either nat- or ent-cholesterol are indistinguishable as assessed by differential scanning calorimetry, x-ray diffraction, and neutral buoyant density measurements (48). In addition, we and others (49–52) have found no enantioselectivity in the interaction of cholesterol with phospholipids. Thus, with respect to their interactions with membrane lipids, nat- and ent-cholesterol appear to function similarly.

We took advantage of the difference in the behavior of the enantiomers of cholesterol in situations involving specific molecular recognition or more general sterol-lipid interactions to gain insight into the molecular mechanism underlying the effects of cholesterol on EGF receptor function. By replacing nat-cholesterol with ent-cholesterol in cholesterol-depleted cells, it was possible to compare the effect of the two enantiomers on EGF receptor phosphorylation.

Ent-cholesterol was found to partition into lipid rafts in direct proportion to its concentration in total cell membranes, indicating that it behaves similarly to nat-cholesterol in its ability to distribute into cell membranes. Furthermore, our studies indicate that nat- and ent-cholesterol have equal abilities to reverse the increase in EGF receptor phosphorylation observed following cholesterol depletion. Both the extent of the reversal and the dose of the sterol required to observe reversal were the same for nat- and ent-cholesterol. In addition, in cholesterol-depleted cells, the EGF receptor and the raft marker protein flotillin shifted out of the low density portion of sucrose density gradients, reflecting the disruption of cholesterol-enriched lipid rafts (19, 21). Nat- and ent-cholesterol were equally capable of reconstituting the lipid rafts, as evidenced by the movement of the EGF receptor and flotillin back into the low density portion of the gradient following repletion with either sterol. Thus, no distinction was made at any level between nat- and ent-cholesterol. These observations indicate that the effect of cholesterol on EGF receptor function and raft integrity is not enantioselective.

Because proteins that possess specific binding sites for cholesterol appear to readily distinguish between nat- and ent-cholesterol, whereas sterol-lipid interactions appear to be non-enantioselective, the present observations suggest that the effects of cholesterol on EGF receptor function are due to effects of the sterol on the physical properties of the membrane. We have shown previously that sterol analogs such as 25-hydroxycholesterol and 7-ketocholesterol differentially affect EGF receptor function when exchanged into cell membranes (21). Because of their additional chemical groups, these analogs impart different properties on the membrane than cholesterol. However, these analogs have an overall molecular shape that is more similar to that of nat-cholesterol than ent-cholesterol. Nonetheless, the receptor discriminated among these sterol analogs that have similar shapes, but impart different properties on the membrane. The present findings show that the receptor does not discriminate between nat- and ent-cholesterol, which have different shapes, but impart similar properties on the membrane. Thus, there appears to be a correlation between the ability of a sterol to alter membrane properties (as compared with cholesterol) and its ability to alter EGF receptor function (as compared with cholesterol). Therefore, although we cannot rule out the possibility that cholesterol binds in a non-enantioselective manner to the EGF receptor, we favor the interpretation that the effects of cholesterol on EGF receptor function are due to cholesterol-induced changes in the physical properties of the cell membrane. It seems likely that any non-enantioselective binding of cholesterol to the EGF receptor would occur at hydrophobic sites that are not specifically regulatory in nature. Such nonspecific interactions would probably be dependent on the lipid composition and physical properties of the membrane and hence would be encompassed in the general membrane level effects of sterols on EGF receptor function.

Because cholesterol is critical for inducing the formation of lipid rafts and because EGF receptors are normally localized to lipid rafts, it is possible that the effects of cholesterol on receptor function are ultimately due to the ability of cholesterol to induce lateral domain formation in membranes. The high concentration of cholesterol within lipid raft domains may affect EGF receptor conformation and function through lipid-based mechanisms involving changes in membrane fluidity,
thickness, or stabilization of a particular conformation of the protein.

In summary, our data indicate that cholesterol depletion induces an increase in the intrinsic kinase activity of the EGF receptor and leads to enhanced site-specific phosphorylation of the receptor. The observation that changes in membrane cholesterol levels alter the pattern of EGF receptor phosphorylation suggests that the extent of activation of individual downstream signaling pathways by EGF could differ depending on the level of cholesterol in the cell membrane. As a variety of pathological conditions, including atherosclerosis and type C1 Niemann-Pick disease (53), lead to alterations in cellular cholesterol levels, it is possible that changes in hormonal signaling occur in diseased cells as a result of underlying problems in cholesterol trafficking. Our data also suggest that the effects of cholesterol on receptor signaling are most likely due to the alteration of membrane cholesterol trafficking. Our data also suggest that the effects of cholesterol on receptor signaling are most likely due to the alteration of membrane cholesterol content could have widespread effects on membrane protein function.

Acknowledgment—We thank Maureen Molsen for expert technical assistance with the monolayer measurements.

REFERENCES

1. Brown, D. A., and London, E. (1998) Annu. Rev. Cell Dev. Biol. 14, 111–136
2. McMullen, T. P., and McElhaney, R. N. (1996) Curr. Opin. Coll. Interface Sci. 1, 83–90
3. Burger, K., Gimpl, G., and Fahrenholz, F. (2000) Mol. Cell. Biol. 20, 7371–7380
4. Chen, Z., and Rand, R. P. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 9135–9142
5. Simons, K., and Ikonen, E. (1997) Annu. Rev. Biochem. 66, 55–89
6. Tice, D. A., Bisciardi, J. S., Nickles, A. L., and Parsons, S. J. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 1415–1420
7. Okabayashi, Y., Kudo, Y., Okutani, T., Sugimoto, Y., Sakaguchi, K., and Kasuga, M. (1994) J. Biol. Chem. 269, 23634–23639
8. Roy, S., Luetterforst, R., Harding, A., Etheridge, M., Stang, E., Rolls, B., Hancock, J. F., and Parton, R. G. (1999) Nat. Cell Biol. 1, 98–105
9. Levkowitz, G., Waterman, H., Ettenberg, S. A., Katz, M., Toogchakou, A. Y., Alroy, I., Lavi, S., Iwai, K., Reiss, Y., Ciechanover, A., Lipkowitz, S., and Yarden, Y. (1999) Mol. Cell. Biol. 19, 3153–3154
10. Crowder, C. M., Weston, E. J., Kumar, A. S., Ostland, R. E., Jr., and Covey, D. F. (2001) J. Biol. Chem. 276, 44369–44372
11. Mannock, D. A., McIntosh, T. J., Jiang, X., Covey, D. F., and McElhaney, R. N. (2003) J. Biol. Chem. 278, 31377–31384
12. Ghosh, D., Lyman, R. L., and Timpson, J. (1970) Chem. Phys. Lipids 2, 173–184
13. Guyer, W., and Bloch, K. (1985) Chem. Phys. Lipids 33, 313–322
14. Simons, K., and Ikonen, E. (1997) Nature 387, 569–572
15. Smart, E. J., Ying, Y.-S., Mineo, C., and Anderson, R. G. W. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 10104–10108
16. Mineo, C., James, G. L., Smart, E. J., and Anderson, R. G. W. (1996) J. Biol. Chem. 271, 11309–11313
17. Waugh, M. G., Lawson, D., and Huaan, J. J. (1999) Biochem. J. 337, 591–597
18. Pike, L. J., Han, X., Chung, K.-N., and Gross, R. (2002) Biochemistry 41, 2075–2083
19. Chen, X., and Resh, M. D. (2002) J. Biol. Chem. 277, 49631–49637
20. Ringerike, T., Glystad, F. D., Levy, F. O., Madsen, I. H., and Stang, E. (2002) J. Cell Sci. 115, 1321–1340
21. Pike, L. J., and Casey, L. (2002) Biochemistry 41, 10315–10322
22. Furuichi, T., and Andersen, R. G. W. (1998) J. Biol. Chem. 273, 22298–22304
23. Goto, T., Saito, S., and Fujishita, Y. (1999) J. Biol. Chem. 274, 16631–16638
24. Savage, R. C., and Cohen, S. (1972) J. Biol. Chem. 247, 7609–7611
25. Westover, E. J., and Covey, D. F. (2003) Steroids 68, 159–166
26. Klein, U., Gimpl, G., and Fahrenholz, F. (1997) Biochemistry 36, 10959–10974
27. Lipkowitz, S., Ciechanover, A., Lipkowitz, S., and Yarden, Y. (1994) Biochem. J. 269, 659–663
28. Downward, J., Parker, P., and Waterfield, M. D. (1984) Nature 311, 483–485
29. Brown, M.-C., Leu, T.-Z., McCarley, D. J., Schatzman, R. C., and Parsons, S. J. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 6981–6985
30. Tice, D. A., Bisciardi, J. S., Nickles, A. L., and Parsons, S. J. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 1415–1420
31. Okabayashi, Y., Kudo, Y., Okutani, T., Sugimoto, Y., Sakaguchi, K., and Kasuga, M. (1994) J. Biol. Chem. 269, 23634–23639
32. Baxter, A. G., Rotin, D., Urena, J. M., Skodnik, E. Y., and Schlessinger, J. (1994) J. Biol. Chem. 269, 31310–31314
33. Roy, S., Luetterforst, R., Harding, A., Apolloni, A., Etheridge, M., Stang, E., Rolle, B., Hancock, J. F., and Parton, R. G. (1999) Nat. Cell Biol. 1, 98–105
34. Levkowitz, G., Waterman, H., Ettenberg, S. A., Katz, M., Toogchakou, A. Y., Alroy, I., Lavi, S., Iwai, K., Reiss, Y., Ciechanover, A., Lipkowitz, S., and Yarden, Y. (1999) Mol. Cell. Biol. 19, 1029–1040
35. Crowder, C. M., Weston, E. J., Kumar, A. S., Ostland, R. E., Jr., and Covey, D. F. (2001) J. Biol. Chem. 276, 44369–44372
36. Mannock, D. A., McIntosh, T. J., Jiang, X., Covey, D. F., and McElhaney, R. N. (2003) J. Biol. Chem. 278, 31377–31384